Skip to content

LSD: all studies

Page 156 of 282: studies 1,551 to 1,560 of 2,815, newest first. Back to the LSD overview

Research

Psychedelics in psychiatric treatment: a literature review

Quality in Sport January 26, 2026 Adam Wolski, Ewa Szplit, Mikołaj Franciszek Patalong et al.

Background: Psychedelic substances have been used for millennia in religious and healing contexts and have recently re-emerged as subjects of scientific interest due to advances in neuroscience and psychiatry. Research suggests that psychedelics may address limitations of conventional psychiatric treatments, particularly in disorders such as major depressive disorder, PTSD, substance use...

RAND: Microdosing surges as millions turned to psychedelics in 2025

Mental Health Weekly January 23, 2026 Valerie A. Canady

Microdosing — once a niche practice whispered about in online forums and tech circles — has firmly entered the mainstream. A new RAND survey suggests that millions of U.S. adults are now taking sub‐perceptual amounts of psychedelics such as psilocybin, LSD and MDMA, often with goals that differ sharply from those associated with traditional, full‐dose use.

DOI: 10.1002/mhw.34732 (opens in new tab) Internet privacy Computer security

Burden of drugs and substance abuse among university students in Kenya

African journal of alcohol and drug abuse. January 22, 2026 Morris Kamenderi, John Muteti, Stephen Kimani et al.

Drugs and substance use among university students has been recognized as a global public health issue. Adolescents are particularly vulnerable to drugs and substance use (DSU) including addiction.This study sought to determine the burden of DSU among university students in Kenya. The study utilized a cross-sectional study design covering a representative sample of 17 public and private...

Psychedelics distinctly alter brain entropy and complexity compared to psychostimulants

medRxiv January 16, 2026 Kristian Larsen, Patrick M. Fisher, Drummond E. Mcculloch et al. 1 citation preprint

Classical psychedelics have regained interest for their potential to treat psychiatric and neurological disorders, and explore neural mechanisms supporting perception, cognition, and mood. Acute psychedelic effects have been linked to increases in brain complexity and entropy, but it is unclear if these changes are specific to psychedelics or reflect more general psychoactive effects. Here, we...

Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model.

ACS Chemical Neuroscience January 7, 2026 Charalampos L. Kandilakis, Costas Papatheodoropoulos

Psychedelics are a diverse class of psychoactive compounds that profoundly alter perception, cognition, and emotional states. Recently, classical serotonergic agents, such as psilocybin and lysergic acid diethylamide (LSD), along with atypical agents such as methylenedioxymethamphetamine (MDMA, ecstasy) and ibogaine, have attracted renewed attention due to their rapid and sustained clinical...

Associations of Couples' Psychedelic Use with Shared Reality and Relational Well-Being.

Journal of Psychoactive Drugs January 6, 2026 Talea Cornelius, Tommaso Barba

The resurgence in research with classic psychedelics (e.g. LSD, psilocybin) underscores their potential for improved well-being; however, the interpersonal context and mechanisms of psychedelic impacts remain unknown. In a sample of 798 participants (81 couples), this survey study tested whether use of a psychedelic with a romantic partner (v. not together) was associated with couples' shared...

DOI: 10.1080/02791072.2025.2607729 (opens in new tab) Couples Romantic relationships Dyads Psychedelics +1

Snapshot IP 1 Detection Following 5-HT 2 A Receptor Stimulation in the Mouse Brain

ACS Chemical Neuroscience January 2, 2026 Mario de la Fuente Revenga, Javier González-Maeso 1 citation

The distinct subjective effects that define psychedelics such as lysergic acid diethylamide (LSD), psilocybin, or 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) as drug class are causally linked to the activation of the serotonin 2A receptor (5-HT 2A R). However, some aspects of 5-HT 2A R pharmacology remain elusive, such as what molecular drivers differentiate psychedelic from...

Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.

JAMA Network Open January 2, 2026 Gianluca Andri Florineth, Isabell Klima, Anna Laura Boeker et al. 5 citations

Psychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessions. Quantitative evidence on how this concomitant therapy contributes to treatment outcomes is limited, highlighting the need for a systematic synthesis. To evaluate whether the quantity of psychological therapy is associated with symptom reduction...

Psychedelics and music: characterising changes in hierarchy of brain dynamics among the Santo Daime

Oxford University Research Archive (ORA) (University of Oxford) 2026 K Jerotic

The last few decades have been characterised by a resurgence in research and clinical interest in classic serotonergic psychedelics including N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD) and psilocybin, with a growing body of literature pointing to their treatment potential. Ayahuasca is a psychedelic brew commonly composed of plants carrying the psychoactive compound DMT, and...

Effects of psychedelics on markers of neuroplasticity in humans

2026 Abigail E. Calder

A growing number of studies suggest that serotonergic psychedelics, including lysergic acid diethylamide (LSD), can rapidly and lastingly stimulate various aspects of neuroplasticity. Neuroplasticity is the nervous system’s fundamental ability to reorganize itself in order to adapt to its environment, and it involves both changes in brain structure and changes in how the brain functions. It is...